comparemela.com
Home
Live Updates
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks : comparemela.com
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
United States ,
American ,
Eugene Schneider ,
Sami Khella ,
Penn Presbyterian Medical Center ,
Astrazeneca ,
Drug Administration ,
Ionis Pharmaceuticals ,
Columbia University Irving Medical Center ,
Clinical Development ,
University Of Pennsylvania School Medicine ,
American Academy Of Neurology Annual Meeting ,
Department Of Neurology ,
Neuropathy Impairment Score ,
Norfolk Quality ,
Life Questionnaire Diabetic Neuropathy ,
Clinical Neurology ,
Pennsylvania School ,
Executive Vice President ,
Chief Clinical Development Officer ,
American Academy ,
Neurology Annual Meeting ,
New Drug Application ,
Orphan Drug Designation ,
Emerging Science ,
Rare Diseases ,
Open Label Phase ,
Neurol Ther ,
University Irving Medical Center ,
Drug Reduces Death ,
Underdiagnosed Form ,
Heart Failure ,
Annual Report ,
Global Phase ,
Antisense Oligonucleotide ,
Astrazeneca Plc Stock Exchange ,
News ,
Information ,
Press Release ,
Positive ,
Results ,
Rom ,
The ,
Hase ,
Wii ,
Trial ,
N ,
Patients ,
Ith ,
Hereditary ,
Amyloid ,
Polyneuropathy ,
Howed ,
Eplontersen ,
Pet ,
Ts Azn Gb0009895292 ,
comparemela.com © 2020. All Rights Reserved.